Cancel
Capsida
Capsida Employees
5 people indexed:
-
90j1vuu.15kg7gjf@935gq8j.4rw Sign up to see email
-
jx1jy.g8yq2@h1vg365.h2y Sign up to see email
-
Nicholas Flytzanis
Founder, Chief Research and Innovation Officer
00e8b27k.8xrrqu2eu@g3g267j.3u9 Sign up to see email8w5jbk87.73ekrw783@9bq8277.ug1 Sign up to see email -
vwq7.2rjz04@jrfhhlf.ly0 Sign up to see email
-
z0yj7e2.y8q3w07l8@17kfh14.e31 Sign up to see email
Capsida Company Information
Capsida, founded in 2019 and based in Thousand Oaks, California, develops targeted, non-invasive intravenous gene therapies for both rare and common diseases across all ages. The company has three wholly owned programs in CNS disorders, including potential treatments for genetic epilepsy due to STXBP1 mutations and Parkinson’s disease associated with GBA mutations. Capsida utilizes proprietary engineered capsids that enable high transduction levels to desired tissues and cells while limiting tropism to non-target organs such as the liver. These IV-delivered capsids exhibit a ~4000-fold difference in CNS expression versus liver targeting relative to naturally occurring AAV9. Capsida’s pipeline includes therapies for CNS and ophthalmology disease indications. The company has entered into strategic partnerships with AbbVie, Lilly, CRISPR Therapeutics, and expanded its partnership with AbbVie to include ophthalmology disorders. Capsida’s cGMP manufacturing facility was commissioned in 2021. The company is financed by Versant Ventures and Westlake Village BioPartners.
Report inaccurate information
Report inaccurate information
